Concepedia

Naveen Kumar

NK

Statistics

Publications

10

Citations

478

H-Index

10

Active since

2012

Affiliations

AstraZeneca (India)(Current)

AstraZeneca (United Kingdom)

AstraZeneca (United States)

TB Alliance

Naveen Kumar is an author at AstraZeneca (India) specializing in mycobacterium tuberculosis infection, pharmacology, and antibacterial pharmacology.

ORCID

Publications per year

2012–2021

10

Publications

10

Azaindoles: Noncovalent DprE1 Inhibitors from Scaffold Morphing Efforts, Kill Mycobacterium tuberculosis and Are Efficacious <i>in Vivo</i>

Pravin S. Shirude, Radha Krishan Shandil, C Sadler et al. · Journal of Medicinal Chemistry · 2013 · 162 citations

, , +14

1,4-Azaindole, a Potential Drug Candidate for Treatment of Tuberculosis

Monalisa Chatterji, Radha Krishan Shandil, M. R. Manjunatha et al. · Antimicrobial Agents and Chemotherapy · 2014 · 109 citations · Full text

, , +15

The Phosphatidyl- <i>myo</i> -Inositol Mannosyltransferase PimA Is Essential for Mycobacterium tuberculosis Growth <i>In Vitro</i> and <i>In Vivo</i>

Francesca Boldrin, Marcello Ventura, Giulia Degiacomi et al. · Journal of Bacteriology · 2014 · 52 citations · Full text

, , +15

Scaffold Morphing To Identify Novel DprE1 Inhibitors with Antimycobacterial Activity

Manjunatha M. R, Radha Krishan Shandil, Manoranjan Panda et al. · ACS Medicinal Chemistry Letters · 2019 · 40 citations · Full text

, , +14

Pharmacokinetics and dose response of anti-TB drugs in rat infection model of tuberculosis

Naveen Kumar, K. G. Vishwas, Mahesh Kumar et al. · Tuberculosis · 2014 · 25 citations · Full text

, , +15

1–5 of 10